In vitro activity of omadacycline against bacterial isolates from bone/joint infections and rare pathogens in the SENTRY antimicrobial surveillance program (2015–2023)
The potent omadacycline activity observed in this study suggests potential clinical utility for treatment of bone/joint infections and rarely encountered Gram-positive infections caused by various staphylococci, streptococci, and enterococci isolates and supports ongoing clinical trials for these disease indications.
Authors
- Christopher G Blankers
- Kelley A. Fedler (ORCID: https://orcid.org/0000-0001-8717-2259)
- Michael D. Huband (ORCID: https://orcid.org/0000-0002-9769-9019)
- Diane Anastasiou
- Paul R. Rhomberg (ORCID: https://orcid.org/0000-0001-6798-7653)
- Mariana Castanheira
- Alisa W. Serio
Institutions
- Paratek Pharmaceuticals (United States) (US)
- JMI Laboratories (US)
Publication Details
- Journal
- Journal of Global Antimicrobial Resistance
- Published
- 2025-05-03
- DOI
- https://doi.org/10.1016/j.jgar.2025.04.027
- Citations
- 1
- Primary Topic
- Orthopedic Infections and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.01